NASDAQ:IMNM Immunome (IMNM) Stock Price, News & Analysis → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free IMNM Stock Alerts $15.63 +0.30 (+1.96%) (As of 12:51 PM ET) Add Compare Share Share Today's Range$15.12▼$15.9050-Day Range$13.73▼$27.3452-Week Range$4.50▼$30.96Volume262,515 shsAverage Volume727,676 shsMarket Capitalization$936.86 millionP/E RatioN/ADividend YieldN/APrice Target$30.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Immunome alerts: Email Address Immunome MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside92.7% Upside$30.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.91) to ($2.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.33 out of 5 starsMedical Sector709th out of 905 stocksPharmaceutical Preparations Industry332nd out of 422 stocks 3.5 Analyst's Opinion Consensus RatingImmunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunome has only been the subject of 3 research reports in the past 90 days.Read more about Immunome's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IMNM. Previous Next 0.0 Dividend Strength Dividend YieldImmunome does not currently pay a dividend.Dividend GrowthImmunome does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMNM. Previous Next 2.0 News and Social Media Coverage News SentimentImmunome has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Immunome this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for IMNM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Immunome to their MarketBeat watchlist in the last 30 days. This is a decrease of -81% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunome insiders have not sold or bought any company stock.Percentage Held by Insiders20.00% of the stock of Immunome is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunome's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunome are expected to decrease in the coming year, from ($1.91) to ($2.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunome is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunome is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunome has a P/B Ratio of 5.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunome's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Immunome Stock (NASDAQ:IMNM)Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Read More IMNM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMNM Stock News HeadlinesMay 8, 2024 | businesswire.comImmunome to Present at 2024 Bank of America Healthcare ConferenceMay 2, 2024 | businesswire.comImmunome Appoints Kinney Horn as Chief Business OfficerMay 8, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. May 1, 2024 | americanbankingnews.comImmunome (NASDAQ:IMNM) Now Covered by Analysts at JPMorgan Chase & Co.April 25, 2024 | businesswire.comImmunome Appoints Sandra M. Swain to Board of DirectorsApril 19, 2024 | finance.yahoo.comImmunome, Inc. (IMNM)April 17, 2024 | msn.comImmunome (IMNM) Price Target Increased by 8.72% to 36.04April 16, 2024 | msn.comGuggenheim Initiates Coverage of Immunome (IMNM) with Buy RecommendationMay 8, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 5, 2024 | businesswire.comImmunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 29, 2024 | investorplace.comIMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023March 28, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Immunome (IMNM)March 28, 2024 | businesswire.comImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired AssetsMarch 28, 2024 | businesswire.comImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired AssetsMarch 27, 2024 | finance.yahoo.comImmunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From AyalaMarch 22, 2024 | finance.yahoo.comImmunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutionsMarch 18, 2024 | msn.comArrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapiesMarch 18, 2024 | businesswire.comArrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer TherapiesMarch 7, 2024 | businesswire.comImmunome to Participate in the Leerink Partners Global Biopharma ConferenceMarch 1, 2024 | businesswire.comImmunome to Participate in the TD Cowen 44th Annual Healthcare ConferenceFebruary 28, 2024 | msn.comBiotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?February 24, 2024 | msn.comImmunome (IMNM) Price Target Increased by 179.17% to 34.17February 22, 2024 | benzinga.comImmunome Stock (NASDAQ:IMNM), Short Interest ReportFebruary 20, 2024 | finance.yahoo.comImmunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsFebruary 20, 2024 | businesswire.comImmunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsFebruary 19, 2024 | finance.yahoo.comIMNM Apr 2024 30.000 callFebruary 19, 2024 | finance.yahoo.comIMNM Mar 2024 10.000 putSee More Headlines Receive IMNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/08/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMNM CUSIPN/A CIK1472012 Webimmunome.com Phone610-321-3700FaxN/AEmployees55Year FoundedN/APrice Target and Rating Average Stock Price Target$30.50 High Stock Price Target$35.00 Low Stock Price Target$24.00 Potential Upside/Downside+99.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($5.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,810,000.00 Net Margins-761.92% Pretax Margin-761.92% Return on Equity-69.74% Return on Assets-31.40% Debt Debt-to-Equity RatioN/A Current Ratio6.63 Quick Ratio6.63 Sales & Book Value Annual Sales$14.02 million Price / Sales65.54 Cash FlowN/A Price / Cash FlowN/A Book Value$2.77 per share Price / Book5.53Miscellaneous Outstanding Shares59,940,000Free Float47,954,000Market Cap$918.88 million OptionableOptionable Beta1.87 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Clay B. Siegall Ph.D. (Age 63)President, CEO & Chairman Mr. Max Rosett (Age 34)Interim CFO & Executive VP of Operations Mr. Robert Lapetina (Age 49)Principal Accounting Officer Mr. Philip RobertsChief Technical OfficerDr. Jack Higgins Ph.D. (Age 44)Chief Scientific Officer Ms. Sandra G. Stoneman Esq. (Age 50)J.D., Chief Legal Officer, General Counsel & Corporate Secretary Comp: $443.43kMr. Bruce Turner M.D. (Age 60)Ph.D., Chief Strategy Officer Dr. Robert J. Lechleider M.D.Chief Medical OfficerMr. Kinney Horn (Age 49)Chief Business Officer More ExecutivesKey CompetitorsOcular TherapeutixNASDAQ:OCULABIVAX Société AnonymeNASDAQ:ABVXARS PharmaceuticalsNASDAQ:SPRYArcutis BiotherapeuticsNASDAQ:ARQTOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsSwiss National BankBought 71,400 shares on 5/7/2024Ownership: 0.119%Sei Investments Co.Bought 18,990 shares on 5/7/2024Ownership: 0.032%Capstone Investment Advisors LLCBought 42,300 shares on 5/1/2024Ownership: 0.071%Clear Creek Financial Management LLCBought 22,153 shares on 4/26/2024Ownership: 0.037%Avidity Partners Management LPBought 1,333,479 shares on 2/14/2024Ownership: 3.121%View All Insider TransactionsView All Institutional Transactions IMNM Stock Analysis - Frequently Asked Questions Should I buy or sell Immunome stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunome in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMNM shares. View IMNM analyst ratings or view top-rated stocks. What is Immunome's stock price target for 2024? 7 brokers have issued 12-month price objectives for Immunome's stock. Their IMNM share price targets range from $24.00 to $35.00. On average, they anticipate the company's stock price to reach $30.50 in the next twelve months. This suggests a possible upside of 92.7% from the stock's current price. View analysts price targets for IMNM or view top-rated stocks among Wall Street analysts. How have IMNM shares performed in 2024? Immunome's stock was trading at $10.70 on January 1st, 2024. Since then, IMNM stock has increased by 47.9% and is now trading at $15.83. View the best growth stocks for 2024 here. When is Immunome's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our IMNM earnings forecast. How were Immunome's earnings last quarter? Immunome, Inc. (NASDAQ:IMNM) released its earnings results on Thursday, March, 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.26. The business had revenue of $3.83 million for the quarter, compared to the consensus estimate of $3.40 million. Immunome had a negative trailing twelve-month return on equity of 69.74% and a negative net margin of 761.92%. What ETF holds Immunome's stock? Invesco DWA SmallCap Momentum ETF holds 573,596 shares of IMNM stock, representing 0.99% of its portfolio. When did Immunome IPO? Immunome (IMNM) raised $30 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 2,500,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Chardan served as the underwriters for the IPO. Who are Immunome's major shareholders? Immunome's stock is owned by many different retail and institutional investors. Top institutional shareholders include Swiss National Bank (0.12%), Capstone Investment Advisors LLC (0.07%), Clear Creek Financial Management LLC (0.04%) and Sei Investments Co. (0.03%). Insiders that own company stock include Bruce Turner, Clay B Siegall, Michael Lefenfeld, Michael Rapp and Purnanand D Sarma. View institutional ownership trends. How do I buy shares of Immunome? Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMNM) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorFidelity, Bezos, Goldman Bet Big on Tiny BiotechBehind the MarketsAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
